<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126257">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156674</url>
  </required_header>
  <id_info>
    <org_study_id>2014LS014</org_study_id>
    <secondary_id>MT2014-08R</secondary_id>
    <nct_id>NCT02156674</nct_id>
  </id_info>
  <brief_title>Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome</brief_title>
  <official_title>Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center study in which Naglazyme® will be given weekly for two years in
      patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who
      have previously been treated with an allogeneic transplant.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in urinary glycosaminoglycan (GAG) excretion</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in urinary glycosaminoglycan (GAG) excretion from baseline to 2 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in distance traveled</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in distance traveled in 6 minute walk and standard tests of range of motion and mobility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in neurocognitive ability</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will undergo full neuropsychological testing annually and abbreviated testing for attention and adaptive skills at the six-month interval visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>development of antibodies to Naglazyme therapy</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>development of antibodies including neutralizing antibodies with weekly Naglazyme therapy and the impact of these antibodies on cardiorespiratory and skeletal parameters as measured by the 6--minute walk test and standard tests of range of motion and mobility, and the change in neurocognitive ability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Maroteaux-Lamy Syndrome</condition>
  <arm_group>
    <arm_group_label>Naglazyme®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly Naglazyme® infusion for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naglazyme®</intervention_name>
    <description>1 mg per kg of body weight administered once weekly as an intravenous infusion</description>
    <arm_group_label>Naglazyme®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) treated with a prior
             allogeneic transplant &gt;2 years previously

          -  Persons currently receiving Naglazyme may be accepted into the study

          -  Age &gt; 2 years

          -  &gt;10% engrafted based on most recent testing

          -  Willing to commit to traveling to the University of Minnesota every 6 months

          -  Written informed consent with parent/guardian consent for children &lt; 18 years of age
             or persons unable to consent with minor assent if appropriate

        Exclusion Criteria:

          -  History of cardiac or pulmonary insufficiency or those requiring continuous
             supplemental oxygen

          -  Pregnant or breastfeeding

          -  Any condition that, in the view of the investigator, places the patient at high risk
             of poor treatment compliance or of not completing the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Braulin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Braunlin, M.D.</last_name>
    <phone>612-626-2755</phone>
    <email>braun002@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>June 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maroteaux-Lamy Syndrome</keyword>
  <keyword>mucopolysaccharide VI</keyword>
  <keyword>MPS VI</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
